

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 11 of 13 of Amendment in Response to September 15, 2011 Office Action and Supplemental Information Disclosure Statement

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the items listed below which are also listed on the Substitute PTO-1449 form attached hereto as **Exhibit A**. Copies of items 1-16 are enclosed herewith as **Exhibits 1-16**, respectively.

1. PCT International Publication No. WO 99/18460, published April 15, 1999; (**Exhibit 1**)
2. Japanese Patent Application Publication No. 06-287167, published October 11, 1994; (**Exhibit 2**)
3. Japanese Patent Application Publication No. 08-231595, published September 10, 1995; (**Exhibit 3**)
4. Donath et al. (1998) "Acute Cardiovascular Effects of Insulin-Like Growth Factor I in Patients With Chronic Heart Failure" J. Clin. Endo. And Metabolism, 83:3177-3183; (**Exhibit 4**)
5. Lee et al. (1999) "Insulin-Like Growth Factor I Improves Cardiovascular Function and Suppresses Apoptosis of Cardiomyocytes in Dilated Cardiomyopathy" Endocrinology 140:4831-4840; (**Exhibit 5**)
6. Norrby (1996) "Interleukin-8 and de novo Mammalian Angiogenesis" Cell Prolif. 29:315-323; (**Exhibit 6**)
7. Saitoh et al. (2001) "Rapid Induction and Ca²⁺ Influx-Mediated Suppression of Vitamin D3 Up-regulated Protein 1 (VDUP1) mRNA in Cerebellas Granule Neurons Undergoing Apoptosis" J. Neurochem. 78:1267-1276; (**Exhibit 7**)
8. Yanagisawa-Miwa et al. (1992) "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor" Science 257:1401-1403; (**Exhibit 8**)
9. December 8, 2011 Notice of Allowance issued in connection

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480

Filed : October 23, 2003

Page 12 of 13 of Amendment in Response to September 15, 2011 Office Action and Supplemental Information Disclosure Statement

with U.S. Serial No. 11/894,581; (**Exhibit 9**)

10. August 23, 2011 Summons to Attend Oral Proceedings issued in connection with European Patent Application No. EP01942041.3; (**Exhibit 10**)
11. November 17, 2011 Second Summons to Attend Oral Proceedings issued in connection with European Patent Application No. EP01942041.3; (**Exhibit 11**)
12. June 28, 2011 Official Action issued in connection with Japanese Patent Applications No. 2002-501968; (**Exhibit 12**)
13. January 4, 2012 Office Action issued in connection with U.S. Serial No. 11/648,769; (**Exhibit 13**)
14. September 6, 2011 Examination Report issued in connection with Australian Patent Application No. 2009213032; (**Exhibit 14**)
15. November 15, 2011 Examination Report issued in connection with Australian Patent Application No. 2009213032; (**Exhibit 15**)
16. Extended European Search Report issued in connection with European Patent Application No. EP11157749.0. (**Exhibit 16**)

The Examiner is respectfully requested to make of record the items listed on the PTO Form 1449 Substitute by initialing and dating the attached PTO Form 1449 Substitute, and returning a copy of the initialed and dated form to applicant's undersigned attorney.


This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. §1.97(c). Accordingly, authorization is hereby given to charge the amount of ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) to Deposit Account No. 03-3125 for filing this Supplemental Information Disclosure Statement.

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 13 of 13 of Amendment in Response to September 15, 2011 Office Action and Supplemental Information Disclosure Statement

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the total fee of \$815.00, including a \$635.00 fee for a three-month extension of time and a \$180.00 fee for filing a Supplemental Information Disclosure Statement, for which the authorization to charge Deposit Account No. 03-3125 has been given above, is deemed necessary in connection with the filing of this Amendment and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicant
Cooper & Dunham LLP
30 Rockefeller Plaza
20th Floor
New York, New York 10112
(212) 278-0400

Certificate of Transmission
I hereby certify that this correspondence is being transmitted via the Electronic Filing System (EFS) to the U.S. Patent and Trademark Office on March 15, 2012.


Xueguang Sun